86 Researchers have identified 63 genetic regions linked to an increased risk of kidney cancer, significantly advancing our understanding of the disease’s genetic architecture. This extensive multi-ancestry genome-wide association study (GWAS), published in Nature Genetics, analysed data from over 29,000 kidney cancer cases and 835,000 controls, unveiling crucial insights that could pave the way for improved screening and treatment strategies. The study is a landmark in cancer genetics, identifying 108 independent risk loci across 63 susceptibility regions, with 50 of these regions being newly discovered. These findings significantly expand the previously known 13 susceptibility regions identified in earlier GWAS. The comprehensive meta-analysis combined data from seven published studies, three major biobanks (UK Biobank, FinnGen, and Biobank Japan), and newly genotyped samples from the National Cancer Institute (NCI) study, ensuring a robust and diverse dataset . One of the most significant discoveries was a variant common in individuals of African ancestry (rs7629500) located in the 3′ untranslated region of the VHL gene. This variant nearly triples the risk of clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer, with an odds ratio of 2.72 . This highlights the importance of including diverse populations in genetic studies to uncover variants that might be missed in more homogeneous groups. In addition to the VHL variant, the study identified 52 regions associated with ccRCC and six regions with papillary renal cell carcinoma (pRCC), another subtype of the disease. The findings underscore the complex genetic underpinnings of kidney cancer and the importance of subtype-specific research . Further analysis revealed that many of the identified variants are linked to hypoxia-inducible factor (HIF) binding sites, suggesting that hypoxia-related mechanisms play a crucial role in kidney cancer development. This enrichment of HIF-binding sites points to the potential involvement of these pathways in tumour growth and survival, providing new avenues for therapeutic intervention . The study also performed cis-expression quantitative trait locus (cis-eQTL) analyses, identifying 83 candidate genes potentially involved in kidney cancer. These genes are associated with various cellular processes, including growth factor signalling and immune response, which could be targeted in future research and treatment . The researchers developed a polygenic risk score (PRS) based on the identified loci, which showed promising predictive capabilities. In a validation set of European ancestry individuals, the PRS demonstrated an area under the curve (AUC) of 0.65, which increased to 0.74 when combined with traditional risk factors such as age, smoking, body mass index (BMI), and hypertension. This improvement in predictive performance highlights the potential of PRS in risk stratification and personalised medicine, enabling more targeted screening and early intervention for those at higher genetic risk of kidney cancer. This study’s inclusion of diverse populations is a critical step towards understanding the genetic basis of kidney cancer across different ancestries. It addresses the disparity in genetic research, which has historically been skewed towards European populations, by highlighting unique genetic risk factors present in African, Latin American, and Asian populations. This approach not only enriches our understanding of kidney cancer genetics but also ensures that the benefits of genetic research are accessible to a broader range of individuals . The identification of these new genetic risk regions opens up numerous possibilities for future research. Further functional studies are needed to understand the biological mechanisms underlying these associations and to explore potential therapeutic targets. The development of more refined polygenic risk scores, incorporating additional genetic and environmental factors, could further enhance their predictive power and clinical utility.